RXRXRECURSION PHARMACEUTICALS, INC.

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals with a Buy and maintains $8 price target. ...

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding ...

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding ...

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in ...

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which ...

The Market Just Told You Which Layer Of AI Biology It Is Paying For

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data ...

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for ...

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following ...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation ...

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, ...

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely watched... ...

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data

USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting... ...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ... ...

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a... ...

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming ...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation ...

Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised ...

Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals with a Equal-Weight and raises the price target from $5 to $5.5. ...

The Future of Intoxication Detection May Be in Your Voice

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement ...

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases. ...

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals with a Buy and maintains $8 price target. ...

Recursion Reports First Quarter Financial Results and Provides Business Update

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, ...

JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals with a Overweight and lowers the price target from $11 to $10. ...

Recursion Announces Board Transition

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will ...